About
Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Limited, the flagship Company of the Torrent Group, is one of the leading pharmaceutical companies having presence in Indian and global markets. The Company is a dominant player in the therapeutic areas of Cardiovascular (CV), Central Nervous System (CNS), Vitamins and Nutrients (VMN), Gastro-Intestinal (GI) and Anti-Diabetes (AD) therapies in India. It has a strong international presence across more than 40 countries with operations in regulated and emerging markets, such as the US, Europe, Brazil and Rest of the World.
The Company operates through its wholly-owned subsidiaries spread across 12 countries with major setups in the US, Germany and Brazil. Apart from this, it has a modern and well-equipped state-of-the-art R&D Centre at Bhat near Ahmedabad, built with an investment of US $ 40 million.
Torrent Pharmaceuticals Limited was founded in 1959 as Trinity Laboratories by Late Shri U. N. Mehta. Trinity was later renamed as Torrent Pharmaceuticals Limited and taken public in July 15th, 1972. In 1980, Company started their first manufacturing facility at Vatva and received first export order in year 1983. In year 1986, it started second manufacturing plant at Chhatral. In the year 1995, Torrent Gujarat Biotech Ltd plant was commissioned.
In the year 1996, the company acquired the Pharma related investments and business of Torrent Exports Ltd and also commissioned the state-of-the-art R&D centre. In the year 1997, India Infusions Ltd was merged with the company. As a part of restructuring, the company formed three new divisions namely, Prima, Vista and Psycan in the year 1999.
During the year 2001-02, the company launched 31 new products, out of which 8 were first time launches in India. The company completed the upgradation and modernization programme for the formulations plant at the total cost of Rs 48 crore. Also, they acquired a small pharmaceutical company, namely Fornex Industrial Farmaceutica Ltda, later renamed as Torrent Do Brasil Ltda, in Brazil for Rs 128 lakh.
During the year, the company divested their entire 50% equity stake in Sanofi Torrent (India) Ltd to their joint venture partner Sanofi Synthelabo, France. Also, they transferred their entire equity holding of 1,95,04,691 shares in the sick industrial undertaking Torrent Gujarat Biotech Ltd to Torrent Pvt Ltd, a company belonging to the promoter group.
During the year 2002-03, the company introduced 28 new products including the line extensions. The company completed the upgradation of bulk drug plant during the year, which was started during the financial year 2001-02. Also, the company incorporated Torrent Pharma GmbH as a wholly owned subsidiary company in Germany.
During the year 2003-04, the company set up a wholly owned subsidiary company, namely Torrent Pharma Inc in USA with the objective of business development in the large, growing and highly profitable North America generic market. Also, they introduced 25 new products during the year.
Torrent Pharma's presence in Germany started with the acquisition of Heumann Pharma from Pfizer in 2004-05. The Company entered into a License Agreement with Novartis granting global rights for further development and commercialization of its patented AGE Breaker Compound to Novartis. Also, they signed research collaboration agreement with AstraZeneca, another leading global pharmaceuticals company with the aim of discovering a novel drug candidate for the treatment of hypertension. The company incorporated Torrent Pharma Philippines Inc as a wholly owned subsidiary in the Philippines, with a view to tap the huge potential in Philippines.
During the year 2005-06, the company successfully completed capacity expansion and consolidation of bulk drug plant at manufacturing unit in Indrad. The company entered into an agreement with Novo Nordisk India Pvt Ltd, a wholly owned subsidiary of Novo Nordisk A/S, Denmark to extend existing contract manufacturing arrangement for manufacture of Human Insulin formulations.
During the year, the company introduced 43 new products in the market. Also, the company launched new divisions AXON and NEURON and expanded their field force in order to tap increasing business opportunities in CNS segment. In April 2006, they launched a new division 'PSYCAN AZUCA' to exclusively cater to the needs of the significant and growing diabetes population in the country.
During the year, the company acquired Heumann Pharma GmbH & Co Generica KG (Heumann) of Germany for a cash consideration of euro 3.31 million (Rs.17.20 crores). Heumann, is engaged in the business of marketing generic medicines in Germany under the brand name 'Heumann'. In March 2006, the company incorporated Laboratorios Torrent SA de CV to seek registrations of their products in Mexico and subsequently launch a basket of products in the cardiovascular, central nervous system and oral anti-diabetes area. In April 2006, the company incorporated Torrent Pharma Japan Co Ltd as a wholly owned subsidiary in Japan, to cover the generic market in the country effectively for future business prospects.
During the year 2006-07, the company launched 49 new products in the market. The manufacturing facilities at Chatral received approval from the US Food and Drug Administration for the API (active pharmaceutical ingredient) and oral solid dosage formulations facilities. The company initiated process of setting up of a new Greenfield manufacturing site in the state of Sikkim to support the growth in domestic market. Also, the company incorporated a subsidiary in Mexico, named Laboratorios Torrent SA de CV, as a first step for entry into the lucrative Mexican market.
During the year 2007-08, the company launched 52 new products in the market. They successfully entered the highly competitive US market with launch of Citalopram. During the year, the company undertook capacity expansion of 30% in tablet formulations at Baddi plant and the project is nearing completion. They also completed development for nine molecules for the European Union market and nine molecules for United States market.
During the year 2008-09, the company made an investment of Rs 2.05 crore in the equity shares of their wholly owned subsidiary Laboratories Torrent, SA De CV, in Mexico. In September 2008, the company received the US Food and Drug Administration approval for anti-hypertension drug amlodipine besylate tablets in multiple strengths and in November 2008, their generic, risperidone, in tablet forms of various strengths, also got the approval.
In 2009, Torrent Pharmaceuticals commissioned a dedicated formulation and packaging unit for manufacturing insulin exclusively for Novo Nordisk. During the year under review, the company entered into license and supply agreement with AstraZeneca for marketing its products in international market.In 2010, Torrent Pharmaceuticals' Baddi plant received OHAS Audit 18001:2007certification. During the year under review, the Baddi facility was approved by the regulatory authority of Uganda. During the year under review, Torrent Pharmaceuticals forayed into the therapeutic areas of gynaecology and oncology. During the year under review, Torrent Pharmaceuticals commissioned a subsidiary in United Kingdom and Romania. During the year under review, Torrent Research Center developed Long Acting Injectables technology.
In 2011, Torrent Pharmaceuticals' Sikkim plant commenced operation. During the year under review, Torrent Research Center developed indigenous Nasal Drug Delivery system. During the year under review, Torrent Pharmaceuticals set up Sparsh, a dedicated division to cater to Dermatology segment.
In 2013, Torrent Pharmaceuticals entered into a licensing agreement with Reliance Life Sciences for three biosimilars - Rituximab, Adalimumab, and Cetuximab.
In 2014, Torrent Pharmaceuticals acquired Elder Pharma's identified Indian branded formulation business in India and Nepal. During the year under review, the company launched Nephro, a dedicated division to cater to the Nephrology segment. During the year under review, Torrent Pharmaceuticals' Dahej plant commenced operations.
In 2015, Torrent Pharmaceuticals acquired 100% stake of Zyg Pharma, a company engaged in manufacturing various dermatological formulations like creams, ointments, gels, lotions, solutions. In 2016, Torrent Pharmaceuticals' Dahej plant received USFDA approval. During the year under review, the company acquired API manufacturing unit of Hyderabad based Glochem Industries Limited.
In 2017, Torrent Pharmaceuticals acquired Unichem's domestic and Nepal business and also its Sikkim manufacturing facility. During the year under review, the company acquired women healthcare brands from Novartis.
In 2018, Torrent Pharmaceuticals acquired US based Bio-Pharm, Inc. (BPI) which includes US FDA registered manufacturing facility. This is Torrent's first overseas manufacturing unit.
As of 31st March, 2019, the Company has 16 subsidiaries, out of which 4 are step down subsidiaries. Bio-Pharm Inc., a wholly owned subsidiary of Torrent Pharma Inc. USA ('TPI') merged with TPI with effect from 1st January, 2019. The merger aims at administrative convenience and to achieve higher operational efficiencies.
As of 31st March, 2020, the Company has 15 subsidiaries, out of which 3 are step down subsidiaries. Aptil Pharma Limited, a wholly owned subsidiary of Torrent Pharma (UK) Limited., UK dissolved w.e.f. 15th October, 2019 and consequently, the business of Aptil was merged into Torrent Pharma (UK) Limited.
During year 2021, Company launched Dapagliflozin & Rivaroxaban in the Cardiovascular therapy, Brivaracetam in the Central Nervous System therapy, Obeticholic Acid within the Gastro Intestinal therapy and NDDS Tapentadol Nasal spray in Pain Analgesic therapy.
During the year 2021-22 , TPL (Malta) Limited, wholly owned subsidiary of the Company and Torrent Pharma (Malta) Limited wholly owned subsidiary of TPL (Malta) Limited were incorporated on 17th August, 2021.
During the year 2022-23, the Company acquired 100% of the equity shares of Curatio Health Care (I) Private Limited (CHPL) and its two wholly owned subsidiaries, at Philippines and Sri Lanka for a total consideration costing Rs. 2000 Crores. Accordingly, Curatio Health Care (I) Private Limited (CHPL) was amalgamated with the Parent Company effective from 14th October, 2022, the Appointed Date.
The Company launched 6 products in the CNS, diabetic and cardio segments with Rivaroxaban and Desvenlafaxine being the two biggest success.
Torrent Pharmaceuticals Ltd
Chairman Speech
Expanding Horizons Deepening Trust
Dear Stakeholders,
I am proud to present Torrent Pharma's 50th Annual
Report and 3rdIntegrated Annual Report, illustrating our sustained efforts to
deliver consistent value to our stakeholders over the past five decades. Despite the
significant global challenges experienced in the past year, such as the Russia-Ukraine
crises that exerted considerable cost pressures on the pharmaceutical industry, I am
delighted to announce that the Company has achieved consistent growth across all major
markets and growth indicators.
The global macroeconomic scenario has been challenging over the past
two years due to the pandemic-induced contraction of the global output, which was further
aggravated by the onset of the
Russia-Ukraine war, creating an unprecedented humanitarian crisis and
contributing to already-growing inflation across the world. Central banks have responded
with synchronised policy rate hikes to curb inflation. Major economies, particularly in
the South Asian region, faced economic stress due to a combination of weaker currencies,
higher import prices, rising costs of living, and a stronger dollar, making debt servicing
more expensive.
However, India has emerged as one of the most rapidly expanding major
economies, demonstrating resilience and a robust recovery. The Indian economy has
successfully rebounded in 2021-22, surpassing many other nations and positioning itself to
return to its pre-pandemic growth trajectory in
2022-23. India has also grappled with the challenge of high inflation
exacerbated by the European turmoil. However, global agencies consistently project India
as the fastest-growing major economy, with growth rates estimated at 6.5-7.0% in 2022-23.
A year of Growth and Resilience
Amid a challenging environment, we delivered strong performance in
2022-23 with a Y-o-Y revenue growth of 13%. The growth was driven by the momentum of our
new launches, the robust performance of top brands, and the strong contribution from the
acquired portfolio. Our operating profitability has also improved by ~7% over the last
five years due to our strong product portfolio, cost optimisation. Despite continued
pricing pressure in the US and a sluggish German market, we remain optimistic about the
future and our ability to drive sustainable growth.
Our India business has continued to grow, backed by our new launches,
growth of top brands, increased field force productivity, and the acquired portfolio of
Curatio Health Care (I) Private Limited ('Curatio'). The Brazil business witnessed a Y-o-Y
growth of 26%, outperforming the industry growth, contributed largely by expanding CNS
franchise and generics business. The rest of the world (RoW) markets continued their
growth trajectory in double-digits. Germany's business witnessed sequential growth
recovery from the second half of the year, backed by new tender wins and growth in
non-tender segments.
Expanding Our Footprints Towards Sustainable Growth
To further strengthen our position, we are focusing on three key areas:
capitalising on high-growth inorganic opportunities, accelerating our branded generics
business, and remaining committed to our ESG priorities.
In 2022-23, we continued to pursue acquisitions to accelerate growth
and further strengthen our market position. Our acquisition of Curatio, the niche player
in Cosmetic Dermatology, marked a key milestone in our growth journey. We are excited to
leverage Curatio's equity to expand our presence through concept selling and
cosmetology-driven portfolios, in sync with Torrent Pharma's derma portfolio.
Moreover, we have also acquired four brands from Dr. Reddy's
Laboratories, enabling us to expand our product portfolio and enter the fields of
Gynaecology and Urology. We have partnered with Boehringer Ingelheim India Pvt. Ltd. to
co-market three novel medications in India, strengthening our overall Diabetes and
Cardiovascular portfolios.
16 %
5-year CAGR in Operating EBITDA
We achieved significant growth in our branded generics business in
2022-23, with India and Brazil leading the way, followed by the RoW. Our growth is driven
by a focused approach to product launches, consistent outperformance of market growth,
building big brands, and improving in-clinic effectiveness.
During the year, we accelerated product launches in India, Brazil, and
RoW markets, with most of these launches delivering high growth and becoming leading
brands in their respective markets. In Brazil, we established a strong foothold by
launching six products in the CNS, diabetic, and cardio segments. Among these products,
Desvenlafaxine was the biggest successes, with market share in prescription rising to 9%
in just 10 months.
Implementing Our ESG Roadmap
Torrent Pharma is committed to sustainability and responsible
practices. We have set ambitious targets for reducing our greenhouse gas emissions and are
constantly exploring new ways to reduce the impact of our operations on the environment.
Towards this, we have been continuously diversifying our energy mix with cleaner fuels and
renewable sources. We will also be identifying interventions to reduce our dependency on
grid electricity. As a part of the ESG roadmap, we have invested in Hybrid Solar-Wind
project to meet our captive power requirement and to reduce our carbon footprints
significantly.
In addition to energy management and emission control, we also aim to
conserve water through rainwater harvesting and reducing freshwater withdrawal through
responsible consumption and various other initiatives. Further, we have prioritised
achieving 100% non-hazardous recycling and zero waste to landfill sites.
Caring for the Community
Driven by our CSR philosophy of "Think of others when you think
about yourself", we are committed to positively impacting people's lives through a
range of projects. Our CSR initiatives are focused on three thrust areas, i.e., healthcare
and hygiene, education, and social welfare. As part of our community healthcare and
hygiene initiatives, we have established a dedicated hospital for children and adults
where we provide free critical care services. We also organise various outreach programmes
to address malnourishment and anaemia in children and promote awareness of women's health
and sanitation.
Beyond healthcare, we are deeply invested in social development and
education. Our employees actively participate in our social welfare programmes, which
reflects our core values and commitment to caring for the community. From the very
beginning, our CSR initiatives have been centred around improving the lives of people, and
we remain steadfast in our efforts to create a positive impact on society.
Road Ahead
Moving forward, our strategic priority would be to consolidate and
strengthen our position in branded generic markets while continuing to focus on
integration of Curatio portfolio. For generic markets, our priority would be to continue
to optimise our cost competitiveness and fortify the R&D pipeline through incremental
filings and launches. Incremental cash generation shall be allocated toward de-leveraging
of the balance sheet over the near to medium term. In addition, our investment in digital
technology and implementation of our ESG roadmap shall further reflect our position as
responsible corporate citizen.
On behalf of the Board of Directors, I would like to extend my
gratitude to our employees and stakeholders for their trust and support, and we look
forward to deepening these relationships as we work together to create value for all.
Regards,
SAMIR MEHTA
Executive Chairman
  Â
Torrent Pharmaceuticals Ltd
Company History
Torrent Pharmaceuticals Limited, the flagship Company of the Torrent Group, is one of the leading pharmaceutical companies having presence in Indian and global markets. The Company is a dominant player in the therapeutic areas of Cardiovascular (CV), Central Nervous System (CNS), Vitamins and Nutrients (VMN), Gastro-Intestinal (GI) and Anti-Diabetes (AD) therapies in India. It has a strong international presence across more than 40 countries with operations in regulated and emerging markets, such as the US, Europe, Brazil and Rest of the World.
The Company operates through its wholly-owned subsidiaries spread across 12 countries with major setups in the US, Germany and Brazil. Apart from this, it has a modern and well-equipped state-of-the-art R&D Centre at Bhat near Ahmedabad, built with an investment of US $ 40 million.
Torrent Pharmaceuticals Limited was founded in 1959 as Trinity Laboratories by Late Shri U. N. Mehta. Trinity was later renamed as Torrent Pharmaceuticals Limited and taken public in July 15th, 1972. In 1980, Company started their first manufacturing facility at Vatva and received first export order in year 1983. In year 1986, it started second manufacturing plant at Chhatral. In the year 1995, Torrent Gujarat Biotech Ltd plant was commissioned.
In the year 1996, the company acquired the Pharma related investments and business of Torrent Exports Ltd and also commissioned the state-of-the-art R&D centre. In the year 1997, India Infusions Ltd was merged with the company. As a part of restructuring, the company formed three new divisions namely, Prima, Vista and Psycan in the year 1999.
During the year 2001-02, the company launched 31 new products, out of which 8 were first time launches in India. The company completed the upgradation and modernization programme for the formulations plant at the total cost of Rs 48 crore. Also, they acquired a small pharmaceutical company, namely Fornex Industrial Farmaceutica Ltda, later renamed as Torrent Do Brasil Ltda, in Brazil for Rs 128 lakh.
During the year, the company divested their entire 50% equity stake in Sanofi Torrent (India) Ltd to their joint venture partner Sanofi Synthelabo, France. Also, they transferred their entire equity holding of 1,95,04,691 shares in the sick industrial undertaking Torrent Gujarat Biotech Ltd to Torrent Pvt Ltd, a company belonging to the promoter group.
During the year 2002-03, the company introduced 28 new products including the line extensions. The company completed the upgradation of bulk drug plant during the year, which was started during the financial year 2001-02. Also, the company incorporated Torrent Pharma GmbH as a wholly owned subsidiary company in Germany.
During the year 2003-04, the company set up a wholly owned subsidiary company, namely Torrent Pharma Inc in USA with the objective of business development in the large, growing and highly profitable North America generic market. Also, they introduced 25 new products during the year.
Torrent Pharma's presence in Germany started with the acquisition of Heumann Pharma from Pfizer in 2004-05. The Company entered into a License Agreement with Novartis granting global rights for further development and commercialization of its patented AGE Breaker Compound to Novartis. Also, they signed research collaboration agreement with AstraZeneca, another leading global pharmaceuticals company with the aim of discovering a novel drug candidate for the treatment of hypertension. The company incorporated Torrent Pharma Philippines Inc as a wholly owned subsidiary in the Philippines, with a view to tap the huge potential in Philippines.
During the year 2005-06, the company successfully completed capacity expansion and consolidation of bulk drug plant at manufacturing unit in Indrad. The company entered into an agreement with Novo Nordisk India Pvt Ltd, a wholly owned subsidiary of Novo Nordisk A/S, Denmark to extend existing contract manufacturing arrangement for manufacture of Human Insulin formulations.
During the year, the company introduced 43 new products in the market. Also, the company launched new divisions AXON and NEURON and expanded their field force in order to tap increasing business opportunities in CNS segment. In April 2006, they launched a new division 'PSYCAN AZUCA' to exclusively cater to the needs of the significant and growing diabetes population in the country.
During the year, the company acquired Heumann Pharma GmbH & Co Generica KG (Heumann) of Germany for a cash consideration of euro 3.31 million (Rs.17.20 crores). Heumann, is engaged in the business of marketing generic medicines in Germany under the brand name 'Heumann'. In March 2006, the company incorporated Laboratorios Torrent SA de CV to seek registrations of their products in Mexico and subsequently launch a basket of products in the cardiovascular, central nervous system and oral anti-diabetes area. In April 2006, the company incorporated Torrent Pharma Japan Co Ltd as a wholly owned subsidiary in Japan, to cover the generic market in the country effectively for future business prospects.
During the year 2006-07, the company launched 49 new products in the market. The manufacturing facilities at Chatral received approval from the US Food and Drug Administration for the API (active pharmaceutical ingredient) and oral solid dosage formulations facilities. The company initiated process of setting up of a new Greenfield manufacturing site in the state of Sikkim to support the growth in domestic market. Also, the company incorporated a subsidiary in Mexico, named Laboratorios Torrent SA de CV, as a first step for entry into the lucrative Mexican market.
During the year 2007-08, the company launched 52 new products in the market. They successfully entered the highly competitive US market with launch of Citalopram. During the year, the company undertook capacity expansion of 30% in tablet formulations at Baddi plant and the project is nearing completion. They also completed development for nine molecules for the European Union market and nine molecules for United States market.
During the year 2008-09, the company made an investment of Rs 2.05 crore in the equity shares of their wholly owned subsidiary Laboratories Torrent, SA De CV, in Mexico. In September 2008, the company received the US Food and Drug Administration approval for anti-hypertension drug amlodipine besylate tablets in multiple strengths and in November 2008, their generic, risperidone, in tablet forms of various strengths, also got the approval.
In 2009, Torrent Pharmaceuticals commissioned a dedicated formulation and packaging unit for manufacturing insulin exclusively for Novo Nordisk. During the year under review, the company entered into license and supply agreement with AstraZeneca for marketing its products in international market.In 2010, Torrent Pharmaceuticals' Baddi plant received OHAS Audit 18001:2007certification. During the year under review, the Baddi facility was approved by the regulatory authority of Uganda. During the year under review, Torrent Pharmaceuticals forayed into the therapeutic areas of gynaecology and oncology. During the year under review, Torrent Pharmaceuticals commissioned a subsidiary in United Kingdom and Romania. During the year under review, Torrent Research Center developed Long Acting Injectables technology.
In 2011, Torrent Pharmaceuticals' Sikkim plant commenced operation. During the year under review, Torrent Research Center developed indigenous Nasal Drug Delivery system. During the year under review, Torrent Pharmaceuticals set up Sparsh, a dedicated division to cater to Dermatology segment.
In 2013, Torrent Pharmaceuticals entered into a licensing agreement with Reliance Life Sciences for three biosimilars - Rituximab, Adalimumab, and Cetuximab.
In 2014, Torrent Pharmaceuticals acquired Elder Pharma's identified Indian branded formulation business in India and Nepal. During the year under review, the company launched Nephro, a dedicated division to cater to the Nephrology segment. During the year under review, Torrent Pharmaceuticals' Dahej plant commenced operations.
In 2015, Torrent Pharmaceuticals acquired 100% stake of Zyg Pharma, a company engaged in manufacturing various dermatological formulations like creams, ointments, gels, lotions, solutions. In 2016, Torrent Pharmaceuticals' Dahej plant received USFDA approval. During the year under review, the company acquired API manufacturing unit of Hyderabad based Glochem Industries Limited.
In 2017, Torrent Pharmaceuticals acquired Unichem's domestic and Nepal business and also its Sikkim manufacturing facility. During the year under review, the company acquired women healthcare brands from Novartis.
In 2018, Torrent Pharmaceuticals acquired US based Bio-Pharm, Inc. (BPI) which includes US FDA registered manufacturing facility. This is Torrent's first overseas manufacturing unit.
As of 31st March, 2019, the Company has 16 subsidiaries, out of which 4 are step down subsidiaries. Bio-Pharm Inc., a wholly owned subsidiary of Torrent Pharma Inc. USA ('TPI') merged with TPI with effect from 1st January, 2019. The merger aims at administrative convenience and to achieve higher operational efficiencies.
As of 31st March, 2020, the Company has 15 subsidiaries, out of which 3 are step down subsidiaries. Aptil Pharma Limited, a wholly owned subsidiary of Torrent Pharma (UK) Limited., UK dissolved w.e.f. 15th October, 2019 and consequently, the business of Aptil was merged into Torrent Pharma (UK) Limited.
During year 2021, Company launched Dapagliflozin & Rivaroxaban in the Cardiovascular therapy, Brivaracetam in the Central Nervous System therapy, Obeticholic Acid within the Gastro Intestinal therapy and NDDS Tapentadol Nasal spray in Pain Analgesic therapy.
During the year 2021-22 , TPL (Malta) Limited, wholly owned subsidiary of the Company and Torrent Pharma (Malta) Limited wholly owned subsidiary of TPL (Malta) Limited were incorporated on 17th August, 2021.
During the year 2022-23, the Company acquired 100% of the equity shares of Curatio Health Care (I) Private Limited (CHPL) and its two wholly owned subsidiaries, at Philippines and Sri Lanka for a total consideration costing Rs. 2000 Crores. Accordingly, Curatio Health Care (I) Private Limited (CHPL) was amalgamated with the Parent Company effective from 14th October, 2022, the Appointed Date.
The Company launched 6 products in the CNS, diabetic and cardio segments with Rivaroxaban and Desvenlafaxine being the two biggest success.
Torrent Pharmaceuticals Ltd
Directors Reports
Torrent Pharmaceuticals Ltd
Company Background
| Incorporation Year | 1972 |
| Registered Office | Torrent House,Off Ashram Road
Ahmedabad,Gujarat-380009 |
| Telephone | 91-79-26599000,Managing Director |
| Fax | 91-79-26582100 |
Sudhir Mehta| Company Secretary | Chintan Trivedi |
| Auditor | B S R & Co LLP |
| Face Value | 5 |
| Market Lot | 1 |
| Listing | BSE,MSEI ,NSE, |
| Registrar | KFin Techologies Ltd
Karvy Selenium Tow-B,31&32 Financial Dist,Nanakramguda ,Hyderabad-500032 |
Torrent Pharmaceuticals Ltd
Company Management
| Director Name | Director Designation | Year |
|---|
| Sudhir Mehta | Chairman Emeritus | 2023 |
| Samir Mehta | Executive Chairman | 2023 |
| Shailesh Haribhakti | Independent Director | 2023 |
| H Khaitan | Independent Director | 2023 |
| Ameera Shah | Independent Director | 2023 |
| Nayantara Bali | Independent Director | 2023 |
| Jinesh Shah | Director (Operation) | 2023 |
| Maurice Chagnaud | Independent Director | 2023 |
| Aman Mehta | Whole Time Director | 2023 |
| Manish Choksi | Independent Director | 2023 |
| Chintan Trivedi | Company Sec. & Compli. Officer | 2023 |
Torrent Pharmaceuticals Ltd
Listing Information
| Listing Information |
|---|
| BSE_500 |
| BSE_HC |
| BSE_200 |
| BSEDOLLEX |
| NIFTYJR |
| CNX500 |
| BSEMID |
| CNXPHARMA |
| CNX100 |
| CNX200 |
| NFT100EQWT |
| BSEALLCAP |
| LMI250 |
| NFT100LV30 |
| BSE100LTMC |
| NFTYLM250 |
| NFTY100ESG |
| NFTYALV30 |
| NFTYHEALTH |
| NF500M5025 |
| NFTYINDMFG |
| NFTYTOTMKT |
| NFTY200A30 |
Torrent Pharmaceuticals Ltd
Finished Product
| Product Name | Unit | Installed
Capacity | Production
Quantity | Sales
Quantity | Sales
Value |
|---|
| Sales | NA | 0 | 0 | 0 | 6665.96 |
| Other Operating Income | NA | 0 | 0 | 0 | 28.04 |
| Export Benefits | NA | 0 | 0 | 0 | 24.77 |
| Compensation&Settlement Income | NA | 0 | 0 | 0 | 19.64 |
| Government Grant Income | NA | 0 | 0 | 0 | 2.19 |
| Income from Product Regst Doss | NA | 0 | 0 | 0 | 1.72 |
| Others | NA | 0 | 0 | 0 | 0 |
| Processing Charges | NA | 0 | 0 | 0 | 0 |
| Excise Duty | NA | 0 | 0 | 0 | 0 |
| Bulk Drugs | Kg | 0 | 0 | 0 | 0 |
| Capsules | No | 0 | 0 | 0 | 0 |
| Injections | Ltr | 0 | 0 | 0 | 0 |
| Liquid Suspension | Ltr | 0 | 0 | 0 | 0 |
| Ointment | Kg | 0 | 0 | 0 | 0 |
| Tablets | No | 0 | 0 | 0 | 0 |
| Vials | No | 0 | 0 | 0 | 0 |